• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

法匹拉韦可引发口蹄疫病毒的致死性诱变及灭绝。

Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus.

作者信息

de Avila Ana Isabel, Moreno Elena, Perales Celia, Domingo Esteban

机构信息

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, E-28049, Madrid, Spain.

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, E-28049, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; Liver Unit, Internal Medicine, Laboratory of Malalties Hepàtiques, Vall d'Hebron Institut de Recerca-Hospital Universitari Vall d'Hebron (VHIR-HUVH), Universitat Autònoma de Barcelona, 08035, Barcelona, Spain.

出版信息

Virus Res. 2017 Apr 2;233:105-112. doi: 10.1016/j.virusres.2017.03.014. Epub 2017 Mar 18.

DOI:10.1016/j.virusres.2017.03.014
PMID:28322918
Abstract

Antiviral agents are increasingly considered an option for veterinary medicine. An understanding of their mechanism of activity is important to plan their administration either as monotherapy or in combination with other agents. Previous studies have shown that the broad spectrum antiviral agent favipiravir (T-705) and its derivatives T-1105 and T-1106 are efficient inhibitors of foot-and-mouth disease virus (FMDV) replication in cell culture and in vivo. However, no mechanism for their activity against FMDV has been proposed. In the present study we show that favipiravir (T-705) can act as a lethal mutagen for FMDV in cell culture. Evidence includes virus extinction associated with increase in mutation frequency in the mutant spectrum of 860 residues of the 3D (polymerase)-coding region, and a decrease of specific infectivity while the consensus nucleotide sequence of the region analyzed remained invariant. The mutational spectrum evoked by favipiravir differs from that observed with other viruses in that no predominant transition type is observed, indicating that a movement towards A,U- or G,C-rich regions of sequence space is not a prerequisite for virus extinction. We discuss prospects for the use of favipiravir to assist in the control of FMDV, and its possible broader use in veterinary medicine as an extension of its current status as antiviral agent for human influenza virus.

摘要

抗病毒药物越来越被视为兽医学的一种选择。了解其作用机制对于规划其作为单一疗法或与其他药物联合使用的给药方式很重要。先前的研究表明,广谱抗病毒药物法匹拉韦(T-705)及其衍生物T-1105和T-1106在细胞培养和体内均是口蹄疫病毒(FMDV)复制的有效抑制剂。然而,尚未有人提出它们抗FMDV的作用机制。在本研究中,我们表明法匹拉韦(T-705)在细胞培养中可作为FMDV的致死诱变剂。证据包括与3D(聚合酶)编码区860个残基的突变谱中突变频率增加相关的病毒灭绝,以及在分析区域的共有核苷酸序列保持不变的情况下特异性感染性的降低。法匹拉韦诱发的突变谱与其他病毒观察到的不同,因为未观察到主要的转换类型,这表明向富含A、U或G、C的序列空间区域移动不是病毒灭绝的先决条件。我们讨论了使用法匹拉韦协助控制FMDV的前景,以及它作为人类流感病毒抗病毒药物的现有地位的延伸在兽医学中可能更广泛应用的可能性。

相似文献

1
Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus.法匹拉韦可引发口蹄疫病毒的致死性诱变及灭绝。
Virus Res. 2017 Apr 2;233:105-112. doi: 10.1016/j.virusres.2017.03.014. Epub 2017 Mar 18.
2
Extinction of Zika Virus and Usutu Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic Drugs.致死突变使寨卡病毒和乌苏图病毒灭绝,揭示了对三种诱变药物敏感性的不同模式。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00380-18. Print 2018 Sep.
3
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus.口蹄疫病毒灭活效率中的诱变与抑制作用
J Virol. 2003 Jun;77(12):7131-8. doi: 10.1128/jvi.77.12.7131-7138.2003.
4
Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis.通过 lethal mutagenesis(致死性诱变)用 favipiravir(法匹拉韦)消灭西尼罗河病毒。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01400-17. Print 2017 Nov.
5
Understanding the Mechanism of the Broad-Spectrum Antiviral Activity of Favipiravir (T-705): Key Role of the F1 Motif of the Viral Polymerase.了解法匹拉韦(T-705)广谱抗病毒活性的机制:病毒聚合酶F1基序的关键作用。
J Virol. 2017 May 26;91(12). doi: 10.1128/JVI.00487-17. Print 2017 Jun 15.
6
Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.基孔肯雅病毒非结构蛋白的突变导致对广谱抗病毒药物法匹拉韦(T-705)产生耐药性。
J Antimicrob Chemother. 2014 Oct;69(10):2770-84. doi: 10.1093/jac/dku209. Epub 2014 Jun 20.
7
Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space.口蹄疫病毒的致死突变涉及序列空间的转变。
J Virol. 2011 Dec;85(23):12227-40. doi: 10.1128/JVI.00716-11. Epub 2011 Sep 14.
8
Favipiravir elicits antiviral mutagenesis during virus replication in vivo.法匹拉韦在体内病毒复制过程中引发抗病毒诱变。
Elife. 2014 Oct 21;3:e03679. doi: 10.7554/eLife.03679.
9
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.RNA 病毒感染序贯抑制剂-诱变剂治疗的潜在益处。
PLoS Pathog. 2009 Nov;5(11):e1000658. doi: 10.1371/journal.ppat.1000658. Epub 2009 Nov 13.
10
Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus.诱变剂和抗病毒抑制剂对口蹄疫病毒的作用。
Virus Res. 2005 Feb;107(2):183-93. doi: 10.1016/j.virusres.2004.11.008.

引用本文的文献

1
Quasispecies theory and emerging viruses: challenges and applications.准种理论与新兴病毒:挑战与应用
Npj Viruses. 2024 Nov 14;2(1):54. doi: 10.1038/s44298-024-00066-w.
2
Antiviral agents and disinfectants for foot‑and‑mouth disease (Review).口蹄疫的抗病毒药物和消毒剂(综述)
Biomed Rep. 2023 Jul 18;19(3):57. doi: 10.3892/br.2023.1639. eCollection 2023 Sep.
3
Favipiravir Suppresses Zika Virus (ZIKV) through Activity as a Mutagen.法匹拉韦通过作为诱变剂的活性抑制寨卡病毒(ZIKV)。
Microorganisms. 2023 May 19;11(5):1342. doi: 10.3390/microorganisms11051342.
4
The extinction time under mutational meltdown driven by high mutation rates.由高突变率驱动的突变崩溃下的灭绝时间。
Ecol Evol. 2022 Jul 6;12(7):e9046. doi: 10.1002/ece3.9046. eCollection 2022 Jul.
5
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity.RNA 病毒的致死性诱变和具有抗病毒诱变活性的已批准药物。
Viruses. 2022 Apr 18;14(4):841. doi: 10.3390/v14040841.
6
Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies.增强核苷的抗病毒效力,用于潜在的广谱抗病毒疗法。
Viruses. 2021 Dec 14;13(12):2508. doi: 10.3390/v13122508.
7
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review.了解法匹拉韦(T-705)在2019年冠状病毒病中的临床应用:一项综述。
Ther Adv Infect Dis. 2021 Dec 4;8:20499361211063016. doi: 10.1177/20499361211063016. eCollection 2021 Jan-Dec.
8
Induced intra- and intermolecular template switching as a therapeutic mechanism against RNA viruses.诱导的分子内和分子间模板转换作为一种针对 RNA 病毒的治疗机制。
Mol Cell. 2021 Nov 4;81(21):4467-4480.e7. doi: 10.1016/j.molcel.2021.10.003. Epub 2021 Oct 22.
9
Distinct Antiretroviral Mechanisms Elicited by a Viral Mutagen.病毒诱变引发的独特抗逆转录病毒机制。
J Mol Biol. 2021 Sep 3;433(18):167111. doi: 10.1016/j.jmb.2021.167111. Epub 2021 Jun 18.
10
Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome.T-705 治疗发热伴血小板减少综合征的临床疗效及抗病毒机制。
Signal Transduct Target Ther. 2021 Apr 16;6(1):145. doi: 10.1038/s41392-021-00541-3.